Cover Page - USD ($) $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Mar. 23, 2026 |
Jun. 30, 2025 |
|
| Cover [Abstract] | |||
| Document Type | 10-K | ||
| Amendment Flag | false | ||
| Entity Central Index Key | 0001885522 | ||
| Document Fiscal Period Focus | FY | ||
| Document Fiscal Year Focus | 2025 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Document Period End Date | Dec. 31, 2025 | ||
| Entity Registrant Name | NEUMORA THERAPEUTICS, INC. | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Entity Incorporation, State or Country Code | DE | ||
| Securities Act File Number | 001-41802 | ||
| Entity Tax Identification Number | 84-4367680 | ||
| Entity Address, Address Line One | 260 Arsenal Place | ||
| Entity Address, Address Line Two | Suite 1 | ||
| Entity Address, City or Town | Watertown | ||
| Entity Address, State or Province | MA | ||
| Entity Address, Postal Zip Code | 02472 | ||
| City Area Code | 857 | ||
| Local Phone Number | 760-0900 | ||
| Title of 12(b) Security | Common stock, par value $0.0001 per share | ||
| Trading Symbol | NMRA | ||
| Security Exchange Name | NASDAQ | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Emerging Growth Company | false | ||
| Entity Small Business | true | ||
| Entity Shell Company | false | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Voluntary Filers | No | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Public Float | $ 63.3 | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Documents Incorporated by Reference [Text Block] | DOCUMENTS INCORPORATED BY REFERENCE Part III incorporates certain information by reference from the registrant’s proxy statement for the 2026 Annual Meeting of Shareholders. Such proxy statement will be filed no later than 120 days after the close of the registrant’s fiscal year ended December 31, 2025. |
||
| Auditor Firm ID | 42 | ||
| Auditor Name | Ernst & Young LLP | ||
| Auditor Location | San Jose, California | ||
| Entity Common Stock, Shares Outstanding | 182,040,945 | ||
| ICFR Auditor Attestation Flag | false | ||
| Auditor Opinion [Text Block] | Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Neumora Therapeutics, Inc. (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles. |